Trial led by St. Jude Children’s Research Hospital investigators finds medication restores sustained attention of many young survivors; work begins on new strategies to help survivors cope with this common challenge. A medicine widely used to treat attention-deficit/hyperactivity disorder (ADHD) also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors, according to a multicenter trial led by St. Jude Children’s Research Hospital investigators.
